专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07541375B2 Azole derivatives and pharmaceutical compositions containing them 失效
标题翻译：唑衍生物和含有它们的药物组合物
公开(公告)号：US07541375B2
公开(公告)日：2009-06-02
申请号：US11782251
申请日：2007-07-24
申请人： Stephen J. Arkinstall , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Yingsheng Zhang , Peter Blume-Jensen
发明人： Stephen J. Arkinstall , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Yingsheng Zhang , Peter Blume-Jensen
IPC分类号： A61K31/415 , C07D233/00
CPC分类号： C07D233/60 , A61K31/41 , A61K31/4164 , A61K31/4178 , A61K31/4439 , C07D233/54 , C07D233/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D249/08 , C07D257/04 , C07D401/12 , C07D405/12
摘要： The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.
摘要翻译：本发明提供取代的吡唑烷酮化合物，以及使用或包含一种或多种这些化合物的治疗方法和药物组合物。本发明的化合物可用于各种疗法，包括治疗或预防各种癌症，炎症，败血性休克，早产，不孕，疼痛和缺血以及与MEK-1和/或ERK-2相关的其它疾病和病症激活。

2. 发明公开

US20230258625A1 DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开
公开(公告)号：US20230258625A1
公开(公告)日：2023-08-17
申请号：US18137113
申请日：2023-04-20
申请人： Peter Blume-Jensen
发明人： Peter Blume-Jensen
IPC分类号： G01N33/50
CPC分类号： G01N33/5041 , G01N2440/14 , G01N2800/7028
摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

3. 发明申请

US20190317077A1 DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开
公开(公告)号：US20190317077A1
公开(公告)日：2019-10-17
申请号：US16430103
申请日：2019-06-03
申请人： Peter Blume-Jensen
发明人： Peter Blume-Jensen
IPC分类号： G01N33/50
摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

4. 发明申请

US20090155804A1 DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开
标题翻译：基于路径路径的生物标记生物标记面板方法，可用于个性化治疗的特定治疗方法
公开(公告)号：US20090155804A1
公开(公告)日：2009-06-18
申请号：US12331356
申请日：2008-12-09
申请人： Peter Blume-Jensen
发明人： Peter Blume-Jensen
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883
摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.
摘要翻译：通过仅治疗反应性患者可以确保药物的功效增加和减少不需要的副作用。在本发明的一个实施方案中，特定药物干扰的信号传导途径与预测生物标志物和动态生物标志物一起导出，其可以在药物治疗之前和之后阅读这些途径的活性，以选择应答者患者群体。在本发明的替代实施方案中，可以鉴定药物不干扰并且已知与某种特定疾病有因果关系的某些核心途径，并且为那些能够排除这些患者的生物标志物得出患有这些药物非影响途径参与与所讨论的具体药物治疗的疾病。

5. 发明申请

US20070293555A1 AZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 失效
标题翻译：氨基酸衍生物和含有它们的药物组合物
公开(公告)号：US20070293555A1
公开(公告)日：2007-12-20
申请号：US11782251
申请日：2007-07-24
申请人： Stephen ARKINSTALL , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Zhang , Peter Blume-Jensen
发明人： Stephen ARKINSTALL , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Zhang , Peter Blume-Jensen
IPC分类号： A61K31/4196 , A61K31/417 , A61P15/08 , A61P29/00 , A61P31/00 , A61P35/00 , A61P9/10
CPC分类号： C07D233/60 , A61K31/41 , A61K31/4164 , A61K31/4178 , A61K31/4439 , C07D233/54 , C07D233/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D249/08 , C07D257/04 , C07D401/12 , C07D405/12
摘要： The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.
摘要翻译：本发明提供取代的吡唑烷酮化合物，以及使用或包含一种或多种这些化合物的治疗方法和药物组合物。本发明的化合物可用于各种疗法，包括治疗或预防各种癌症，炎症，败血性休克，早产，不孕，疼痛和缺血以及与MEK-1和/或ERK-2相关的其它疾病和病症激活。

6. 发明申请

US20170067877A9 DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开
标题翻译：基于路径路径的生物标记生物标记面板方法，可用于个性化治疗的特定治疗方法
公开(公告)号：US20170067877A9
公开(公告)日：2017-03-09
申请号：US13954080
申请日：2013-07-30
申请人： Peter Blume-Jensen
发明人： Peter Blume-Jensen
IPC分类号： G01N33/50
CPC分类号： G01N33/5041 , G01N2440/14 , G01N2800/7028
摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.
摘要翻译：通过仅治疗反应性患者可以确保药物的功效增加和减少不需要的副作用。在本发明的一个实施方案中，特定药物干扰的信号传导途径与预测生物标志物和动态生物标志物一起导出，其可以在药物治疗之前和之后阅读这些途径的活性，以选择应答者患者群体。在本发明的替代实施方案中，可以鉴定药物不干扰并且已知与某种特定疾病有因果关系的某些核心途径，并且为那些能够排除这些患者的生物标志物得出患有这些药物非影响途径参与与所讨论的具体药物治疗的疾病。

7. 发明申请

US20050054706A1 Pharmaceutically active compounds and methods of use 有权
标题翻译：药物活性化合物和使用方法
公开(公告)号：US20050054706A1
公开(公告)日：2005-03-10
申请号：US10491902
申请日：2002-10-23
申请人： Stephen Arkinstall , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Zhang , Peter Blume-Jensen
发明人： Stephen Arkinstall , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Zhang , Peter Blume-Jensen
IPC分类号： A61K31/41 , A61K31/4164 , A61K31/417 , A61K31/4178 , A61K31/4196 , A61K31/4439 , A61P1/04 , A61P1/14 , A61P1/18 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/02 , A61P7/06 , A61P7/10 , A61P9/00 , A61P9/14 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/06 , A61P15/08 , A61P15/10 , A61P17/00 , A61P17/02 , A61P19/00 , A61P19/02 , A61P19/10 , A61P25/04 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/60 , C07D233/61 , C07D233/68 , C07D249/08 , C07D257/04 , C07D401/12 , C07D405/12 , A61K31/415 , A61K31/416
CPC分类号： C07D233/60 , A61K31/41 , A61K31/4164 , A61K31/4178 , A61K31/4439 , C07D233/54 , C07D233/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D249/08 , C07D257/04 , C07D401/12 , C07D405/12
摘要： The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.
摘要翻译：本发明提供取代的吡唑烷酮化合物，以及使用或包含一种或多种这些化合物的治疗方法和药物组合物。本发明的化合物可用于各种疗法，包括治疗或预防各种癌症，炎症，败血性休克，早产，不孕，疼痛和缺血以及与MEK-1和/或ERK-2相关的其它疾病和病症激活。

8. 发明申请

US20150037810A1 DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开
公开(公告)号：US20150037810A1
公开(公告)日：2015-02-05
申请号：US13954080
申请日：2013-07-30
申请人： Peter Blume-Jensen
发明人： Peter Blume-Jensen
IPC分类号： G01N33/50
CPC分类号： G01N33/5041 , G01N2440/14 , G01N2800/7028
摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

9. 发明申请

US20070225202A1 Methods for Identifying Modulators of Active Kit Tyrosine Kinase Receptor 审中-公开
标题翻译：鉴定活性成分酪氨酸激酶受体调节剂的方法
公开(公告)号：US20070225202A1
公开(公告)日：2007-09-27
申请号：US10579286
申请日：2004-12-06
申请人： Julian Andreev , Brian Healey , Peter Blume-Jensen , Stephen Arkinstall , Rong Dong
发明人： Julian Andreev , Brian Healey , Peter Blume-Jensen , Stephen Arkinstall , Rong Dong
IPC分类号： A61K31/00 , C07K16/00 , G01N33/567
CPC分类号： G01N33/5011 , C07K16/2803 , C07K16/44 , C07K2317/34 , G01N33/566 , G01N33/574 , G01N2333/9121 , G01N2500/04
摘要： The present invention relates to cell-based assays useful for screening for modulators, such as inhibitors, of activated mutant KIT tyrosine kinase receptors, which are associated with mast cell-related disorders, such as mastocytosis and various types of cancer. The invention further provides for the treatment of mast cell-related disorders with an inhibitor identified by the screening method.
摘要翻译：本发明涉及用于筛选与肥大细胞相关病症如肥大细胞增多症和各种类型的癌症有关的活化突变型KIT酪氨酸激酶受体的调节剂如抑制剂的基于细胞的测定法。本发明还提供了通过筛选方法鉴定的抑制剂治疗肥大细胞相关病症。

10. 发明授权

US07253199B2 Azole derivatives and pharmaceutical compositions containing them 有权
标题翻译：唑衍生物和含有它们的药物组合物
公开(公告)号：US07253199B2
公开(公告)日：2007-08-07
申请号：US10491902
申请日：2002-10-23
申请人： Stephen J. Arkinstall , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Yingsheng Zhang , Peter Blume-Jensen
发明人： Stephen J. Arkinstall , Antonio Arulanandam , Xuliang Jiang , Sharad Magar , Roustem Nabioullin , John Yingsheng Zhang , Peter Blume-Jensen
IPC分类号： A61K31/415 , C07D233/00
CPC分类号： C07D233/60 , A61K31/41 , A61K31/4164 , A61K31/4178 , A61K31/4439 , C07D233/54 , C07D233/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D249/08 , C07D257/04 , C07D401/12 , C07D405/12
摘要： The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.
摘要翻译：本发明提供取代的吡唑烷酮化合物，以及使用或包含一种或多种这些化合物的治疗方法和药物组合物。本发明的化合物可用于各种疗法，包括治疗或预防各种癌症，炎症，败血性休克，早产，不孕，疼痛和缺血以及与MEK-1和/或ERK-2相关的其它疾病和病症激活。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式